Northstrive Biosciences Expands IP Portfolio
Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB), is paving the way for advancements in obesity and animal health with its latest patent filings. The company recently announced the submission of four patent applications that showcase its commitment to innovative solutions through its candidates, EL-22 and EL-32. These applications cover both animal health markets and strategies for treating muscle loss in obese patients, making significant strides in the biopharmaceutical landscape.
New Patent Filings Overview
The newly filed patents are focused on varied applications of EL-22 and EL-32, reinforcing Northstrive’s dedication to research and development. Let’s look at the four patents:
1. EL-22 in Animals: This filing introduces a fusion protein of Myo-2 aimed at enhancing muscle growth in animals (Patent Application No. 19/191,246).
2. EL-32 in Obesity: The patents comprising this make up two filings—one for a pharmaceutical composition intended to treat muscle loss caused by obesity treatments (Patent Application No. 19/191,209), and another for a combination therapy utilizing GLP-1 receptor agonists (Patent Application No. 19/191,226).
3. EL-32 for Animals: This application, titled Animal Feed Additive to Encourage Muscle Growth, further expands potential usage in animal health (Patent Application No. 19/191,258).
Significance of the Patents
These strategically timed patent applications bolster Northstrive's engineered probiotic platform, designed not only to transform obesity care but also to extend its benefits into the animal health market. By focusing on preserving muscle mass while reducing fat, Northstrive positions itself uniquely in its pursuit of enhancing health outcomes.
Deniel Mero, Co-Founder of Northstrive, shared, "We believe that EL-22 and EL-32 have the potential to treat obesity effectively in conjunction with GLP-1 receptor agonists, while also providing a solid foundation for developing animal health products." This statement underscores the company’s focus on broadening its impact beyond human health, extending to animal well-being as well.
Current Patent Portfolio
With this latest update, Northstrive's patent portfolio now encompasses eight applications alongside five issued patents. This comprehensive range of intellectual property rights offers robust protection in vital markets, including notable regions like the USA, Japan, China, and Korea. In doing so, Northstrive ensures its innovative therapies are safeguarded against competition, enhancing its market position.
About Northstrive Biosciences
As a key player in biopharmaceuticals, Northstrive Biosciences Inc. focuses on both the development and acquisition of advanced aesthetic medications. Through its primary asset, EL-22, Northstrive employs an innovative probiotic strategy that tackles one of the critical challenges in obesity: maintaining muscle mass during weight loss—a major concern for those utilizing GLP-1 receptor agonists. To explore more about their mission and initiatives, please visit www.northstrivebio.com.
About PMGC Holdings Inc.
PMGC Holdings Inc. serves as a diversified holding company, managing a diverse portfolio through strategic acquisitions and investments across various sectors. Its current portfolio includes three wholly-owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. The commitment to exploring new opportunities remains firm as the company aims to maximize its growth and value.
Frequently Asked Questions
What are the key objectives of Northstrive's recent patent filings?
Northstrive's recent patents aim to protect innovative treatments addressing obesity and promoting muscle growth in both humans and animals, enhancing their market position.
How do EL-22 and EL-32 contribute to obesity treatment?
Both candidates leverage engineered probiotics to support muscle retention during weight loss efforts, potentially in combination with existing therapies like GLP-1 receptor agonists.
What regions are covered by Northstrive's patent portfolio?
Northstrive's patent portfolio offers protection in key markets including the USA, Japan, China, and Korea.
Who is the key spokesperson for Northstrive?
Deniel Mero, Co-Founder of Northstrive, frequently communicates the company’s vision and progress, advocating for innovations in obesity care.
What is the significance of their engineered probiotic approach?
This approach aims to preserve muscle mass while assisting in fat reduction, addressing critical healthcare challenges associated with obesity treatments.
